Regulatory Frameworks

Comprehensive Guide to FDA Orphan Drug Designation for Rare Disease Clinical Trials

Posted on digi By digi

The Orphan Drug Designation (ODD) program, administered by the U.S. Food and Drug Administration (FDA), was established under the Orphan Drug Act of 1983 to incentivize the development of treatments for rare diseases—defined in the U.S. as conditions affecting fewer than 200,000 individuals. This designation grants sponsors access to significant regulatory, financial, and marketing benefits designed to offset the high cost and risk of developing therapies for small patient populations.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Frameworks

How EMA’s PRIME Scheme Accelerates Rare Disease Therapies

Posted on digi By digi

The Priority Medicines (PRIME) scheme was launched by the European Medicines Agency (EMA) in 2016 to enhance support for the development of medicines targeting unmet medical needs. PRIME provides early and proactive regulatory assistance to optimize development plans and accelerate evaluation for therapies that demonstrate potential to significantly benefit patients—particularly in rare and orphan indications where options are limited or non-existent.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Frameworks

ICH Guidelines for Rare Disease Clinical Trials: A Step-by-Step Compliance Roadmap

Posted on digi By digi

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) plays a pivotal role in harmonizing clinical trial regulations across regions. While ICH guidelines are broadly applicable, their practical implementation in rare disease clinical trials requires special consideration due to challenges such as small patient populations, ethical complexity, and accelerated development needs.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Frameworks

Post-Approval Safety Monitoring Requirements for Orphan Drugs

Posted on digi By digi

Orphan drugs offer hope for patients with rare diseases, but their approval often comes with limited pre-market safety data due to small trial populations. This makes post-approval safety monitoring essential. Regulatory authorities such as the FDA, EMA, and other global agencies require orphan drug sponsors to implement robust pharmacovigilance systems that continue to evaluate risks after market entry. These requirements ensure long-term patient safety, especially for therapies granted accelerated or conditional approval.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Frameworks

7-Year Market Exclusivity for Orphan Drugs: Benefits and Pitfalls

Posted on digi By digi

The U.S. Orphan Drug Act (ODA) of 1983 was enacted to stimulate the development of therapies for rare diseases — defined as conditions affecting fewer than 200,000 individuals in the United States. One of its key incentives is the grant of **7 years of market exclusivity** for approved orphan-designated drugs. This exclusivity prevents the FDA from approving any other application for the same drug for the same indication, even in the absence of patent protection.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Frameworks

Tax Credits and Grants for Rare Disease Clinical Development

Posted on digi By digi

Developing therapies for rare diseases presents significant financial challenges. With small patient populations, limited market sizes, and complex trial designs, the return on investment is often uncertain. To bridge this gap, governments and regulatory agencies provide a range of financial incentives — including tax credits and development grants — aimed at encouraging investment in orphan drug research.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Frameworks

Designing Pediatric Investigation Plans for Rare Disease Treatments

Posted on digi By digi

A Pediatric Investigation Plan (PIP) is a regulatory requirement in the European Union (EU) for all new medicines, including those intended for rare diseases. Administered by the European Medicines Agency (EMA), PIPs aim to ensure that medicines developed for adults are also evaluated for their potential use in children, unless a waiver or deferral is granted.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Frameworks

Conditional Marketing Authorization Pathways for Rare Disease Therapies

Posted on digi By digi

Conditional Marketing Authorization (CMA) is a regulatory pathway in the European Union that allows for the early approval of medicines that address serious or life-threatening diseases, especially where there is an unmet medical need — including rare and orphan conditions. Administered by the European Medicines Agency (EMA), this pathway provides faster access to patients while requiring the sponsor to complete confirmatory studies post-approval.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Frameworks

How Priority Review Vouchers Drive Rare Disease Drug Development

Posted on digi By digi

The Priority Review Voucher (PRV) is a regulatory incentive offered by the U.S. Food and Drug Administration (FDA) to encourage drug development for underserved populations, particularly in rare and neglected diseases. The PRV allows the sponsor to expedite FDA review of a subsequent new drug application (NDA) or biologics license application (BLA), reducing the review time from the standard 10 months to 6 months.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Frameworks